Conexeu Sciences Inc. (CNXU) - 10-Q Summary
Business Context and Reporting Period
Company: Conexeu Sciences Inc.
Reporting Period: Quarter and six months ended April 30, 2026.
Business Model: Early-stage regenerative medicine company developing cellular therapies for skin restoration in wound care and aesthetics. The company has no commercial revenue and relies on capital raising to fund operations.
Status: Listed on Nasdaq (Symbol: CNXU) effective May 21, 2026 (Subsequent Event). Classified as an Emerging Growth Company and Smaller Reporting Company.
Key Financial Metrics
| Metric | Six Months Ended April 30, 2026 |
Six Months Ended April 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,023,106) | $(748,114) |
| Operating Expenses | $4,103,327 | $790,434 |
| Cash & Cash Equivalents | $6,848,064 | $4,808,965 (Oct 31, 2025) |
| Restricted Cash | $453,974 | $25,155 (Oct 31, 2025) |
| Total Assets | $8,199,679 | $7,688,711 (Oct 31, 2025) |
| Accumulated Deficit | $(8,544,626) | $(4,521,520) (Oct 31, 2025) |
| Working Capital | $6,910,389 | N/A |
Cash Flow (Six Months Ended April 30, 2026):
- Operating: $(3,340,281)
- Investing: $(34,831)
- Financing: $5,843,030 (Driven by private placements and warrant inducement program)
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased by approximately 419% year-over-year (from $790k to $4.1M). This is primarily due to:
- Consulting: Increased from $196k to $1.76M (regulatory and capital market advisors).
- Management Salaries: Increased from $293k to $1.34M (expansion of executive team and stock-based compensation).
- Professional Fees: Increased from $101k to $593k (legal/accounting costs for public listing).
- Capital Raising: Significant financing activity occurred, including non-brokered private placements and a Regulation Crowdfunding offering, resulting in net proceeds of approximately $2.94M from private placements and $4.49M from Reg CF (closed in prior fiscal year but impacting current liquidity).
- Stock-Based Compensation: Non-cash stock-based compensation increased to $494,453 for the six-month period (up from $91k in the prior year).
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern within one year without additional financing. Management estimates a cash runway of 9 to 11 months from April 30, 2026, based on a projected monthly burn rate of ~$700,000.
- Strategic Milestones:
- Nasdaq Listing: Achieved on May 21, 2026 (Subsequent Event).
- Regulatory: Advancing toward a planned 510(k) submission to the FDA. Management anticipates submission by February 28, 2027.
- Operations: Commenced a new laboratory lease on May 1, 2026.
- Risks:
- Dependence on a single device candidate (CXU™) with no commercial sales.
- Need for additional equity or debt financing to fund operations and development.
- Material weakness in internal controls over financial reporting regarding prepaid expenses (addressed with new procedures).
- Subsequent Events:
- Issued 4.3M shares and warrants under the Warrant Incentive Program (May 2026) for ~$1.97M proceeds.
- Accelerated expensing of $137,377 in prepaid stock-based compensation due to early termination of a vendor agreement.
- Board expansion from 6 to 9 members and appointment of a new Chief Commercial Officer (CCO).
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the 9-11 month cash runway estimate given the increased burn rate of $700k/month.
- Related Party Transactions: Review Note 10 for significant compensation and consulting fees paid to directors and related entities (e.g., Director 7's company investing $2M+).
- Stock-Based Compensation: Assess the impact of the $494k non-cash expense and future vesting obligations on future dilution.
- Internal Controls: Confirm the effectiveness of the new procedures implemented to address the material weakness in prepaid expense accounting.
- Regulatory Timeline: Monitor progress toward the anticipated February 2027 FDA 510(k) submission date.